CpG Oligonucleotides as Vaccine Adjuvants.

Abstract

CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides specifically designed to stimulate Toll-like receptor 9. TLR9 is expressed on human plasmacytoid dendritic cells and B cells and triggers an innate immune response characterized by the production of Th1 and pro-inflammatory cytokines. This chapter reviews recent progress in understanding the mechanism of action of CpG ODN and provides an overview of human clinical trial results using CpG ODN to improve vaccines for the prevention/treatment of cancer, allergy, and infectious disease.

• Authors: Neslihan Kayraklioglu, Begum Horuluoglu, Dennis M Klinman
• Journal: Methods in molecular biology (Clifton, N.J.) (Methods Mol Biol) Vol. 2197 Pg. 51-85 ( 2021) ISSN: 1940-6029 [Electronic] United States
• PMID: 32827132 (Publication Type: Journal Article, Review)

Chemical References

• Adjuvants, Immunologic
• Allergens
• Biomarkers
• CPG-oligonucleotide
• Oligodeoxyribonucleotides
• Toll-Like Receptor 9
• Vaccines
• Vaccines, DNA

Topics

• Adjuvants, Immunologic
• Allergens (immunology)
• Animals
• Biomarkers
• Clinical Studies as Topic
• Drug Evaluation, Preclinical
• Host-Pathogen Interactions (immunology)
• Humans
• Immunity
• Oligodeoxyribonucleotides
• Signal Transduction
• Toll-Like Receptor 9 (metabolism)
• Vaccines (administration & dosage, immunology)
• Vaccines, DNA (genetics, immunology)